Clinical trials: Malaria Diagnosis
Malaria
PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults
This is an open-label evaluation of the safety, tolerability, immunogenicity and efficacy of PfSPZ Vaccine administered by direct venous inoculation (DVI) in healthy, malaria-naïve adult subjects.
- Trial name
- NCT02601716
- Testing
- PfSPZ Vaccine, CHMI (7G8), CHMI (NF135.C10)
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Plasmodium Falciparum Malaria (Drug Resistant)
Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites
The purpose of this study is to provide a new drug combination for a better treatment of P. falciparum for a faster parasite clearance and to counteract artemisinin resistance.
- Trial name
- Artesynib (NCT03697668)
- Testing
- Imatinib, Dihydroartemisinin-piperaquine
- Where
- Vietnam
- Volunteers
- 50 people
- Sponsor
- Nurex S.r.l.
Malaria, Falciparum
Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria
Chlorproguanil-dapsone has been approved for the treatment of uncomplicated Plasmodium falciparum malaria in a number of countries across sub-Sahara Africa, and by the UK's Medicines and Healthcare products Regulatory Agency.
- Trial name
- NCT00344006
- Testing
- chlorproguanil-dapsone-artesunate, artemether-lumefantrine
- Where
- 9 sites in Burkina Faso, Ghana and 3 more
- Volunteers
- 1,395 people
- Sponsor
- GlaxoSmithKline
Malaria, Malaria Vaccines
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
GSK Biologicals in partnership with the Malaria Vaccine Initiative at PATH is developing a candidate malaria vaccine GSK 257049 for the routine immunization of infants and children living in malaria endemic areas.
- Trial name
- NCT00289185
- Testing
- RTS,S/AS02D, Engerix-B®, TETRActHib™
- Where
- Tanzania
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Falciparum
Azithromycin in Combination With Chloroquine Versus Chloroquine in the Eradication of Asymptomatic Plasmodium Falciparum
The purpose of this study is to determine if Azithromycin in combination with chloroquine is superior to chloroquine alone in eradicating P. falciparum asexual parasitemia in asymptomatic, semi-immune adults in Western Kenya.
- Trial name
- NCT00082563
- Testing
- Azithromycin/Chloroquine, Chloroquine
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Malaria
Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.
This trial will evaluate the safety, tolerability, and immunogenicity of PfSPZ Vaccine in healthy Equatoguinean adults, adolescents, children and infants who receive doses of 0.9x10^6, 1.8x10^6 or 2.7x10^6 PfSPZ Vaccine via…
- Trial name
- NCT02859350
- Testing
- PfSPZ Vaccine, PfSPZ Challenge (for CHMI), Normal Saline
- Where
- Equatorial Guinea
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine
The primary objective is to estimate the relative bioavailability of fixed azithromycin / chloroquine combination tablets relative to co-administered individual tablets of azithromycin and chloroquine.
- Trial name
- AZCQ (NCT00844207)
- Testing
- Fixed combination of Azithromycin and Chloroquine, Azithromycin and Chloroquine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Malaria,Falciparum
MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine
First-in-Human, Randomised, Dose-Finding Single Center Study to evaluate three dose levels of a novel malaria vaccine, MSP3-CRM-Vac4All/ Alhydrogel® : 3 µg, 10 µg and 30 µg
- Trial name
- MSP3CRMV4All (NCT05197751)
- Testing
- MSP3-CRM-Vac4All/ Alhydrogel®
- Where
- Mali
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Vac4All
Sepsis Newborn, Malaria
Immune Dysfunction in Newborn Sepsis
The aim of the project is to study neonatal immune dysfunction associated to the risk of newborn sepsis in a malaria endemic area in Benin.
- Conditions
- Sepsis Newborn, Malaria, Immune Responses
- Trial name
- RECIPAL (NCT03780712)
- Testing
- Non applicable
- Volunteers
- 585 people
- Sponsor
- BioMérieux
Malaria
A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
The purpose of this study is to evaluate the safety and immunogenicity of reduced antigen doses and alternative vaccination regimes for RTS,S/AS01E in healthy children aged 5-60 months in a malaria-endemic area.
- Trial name
- NCT07036159
- Testing
- RTS,S/AS01E vaccine
- Where
- 2 sites in Rwanda
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Vivax
Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria
This is a prospective, double-blind, double-dummy, multicenter, comparative study. A total of 300 subjects will be randomized to treatment on Day 1, of which a minimum of 50 female subjects must be enrolled that display moderate…
- Trial name
- NCT02216123
- Testing
- Tafenoquine, Chloroquine, Primaquine
- Where
- 10 sites in Brazil, Colombia and 4 more
- Volunteers
- 251 people
- Sponsor
- GlaxoSmithKline
Malaria
Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks
Primary objective is to demonstrate the non-inferiority of PCR (Polymerase Chain Reaction) adjusted adequate clinical and parasitological response at Day 28 of Coarsucam versus Coartem, based on the first malaria attack of each…
- Trial name
- SMART-CURE (NCT00699920)
- Testing
- Coarsucam, Coartem
- Where
- Uganda
- Volunteers
- 413 people
- Sponsor
- Sanofi
Malaria
Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
This first-in-human clinical trial, was a dose escalation multi-center trial designed to assess the safety, tolerability, and immunogenicity of the vaccine component, BNT165b1, a ribonucleic acid (RNA)-lipid nanoparticle (LNP)…
- Trial name
- NCT05581641
- Testing
- BNT165b1
- Where
- 5 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Malaria
Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria
Primary Objective: To assess the antiparasitic activity of intramuscular (IM) SAR97276A based on parasite reduction ratio at 72 hours in pediatric patients with uncomplicated malaria Secondary Objectives: To assess the evolution…
- Trial name
- NCT01445938
- Testing
- SAR97276A, arthemeter + lumefantrine (ACTs)
- Where
- 4 sites in Benin, Burkina Faso and 2 more
- Volunteers
- 20 people
- Sponsor
- Sanofi
Malaria
A Comparative Safety and Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate in African Adult Patients With Uncomplicated Malaria
The primary objective is to assess the safety of different doses of ferroquine with artesunate (AS) in adult African patients with uncomplicated malaria.
- Trial name
- NCT00563914
- Testing
- ferroquine (SSR97193), amodiaquine
- Where
- 2 sites in Gabon, Kenya
- Volunteers
- 72 people
- Sponsor
- Sanofi
Malaria,Falciparum
MSP3-CRM-Vac4All/ Alhydrogel® Vaccine
Two-arm, randomized, double-blinded and controlled clinical trial to first assess the safety and tolerability of the vaccine in a Phase 1b trial and proceed to assess its efficacy against clinical malaria in young children living…
- Trial name
- NCT05776017
- Testing
- MSP3-CRM-Vac4All/ Alhydrogel®, Anti-Rabies Vaccine
- Where
- Mali
- Volunteers
- 465 people, healthy volunteers welcome
- Sponsor
- Vac4All
Malaria
Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children
GSK Biologicals is developing a number of candidate malaria vaccines for the routine immunization of infants and children living in malaria-endemic areas.
- Trial name
- NCT00307021
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
- Where
- Gabon
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria
The present study aims to investigate and to assess possible neurological and neuropsychiatric events in young children in west Africa with uncomplicated P.
- Trial name
- NCT00978172
- Testing
- artesunate and mefloquine
- Where
- Cameroon
- Volunteers
- 220 people
- Sponsor
- Mepha Ltd.
Malaria
Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria
The purpose of this study is to describe the pediatric and adult patients (U.S. and foreign residents) diagnosed with malaria and treated with artemether-lumefantrine with regard to their demographics, including evaluation of…
- Trial name
- NCT01228344
- Testing
- Artemether-lumefantrine
- Where
- United States
- Volunteers
- 324 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Sequential Optimization of Dose and Schedule of PfSPZ Vaccine
MAVACHE is a sequential dose and schedule optimization trial of intravenous immunization with PfSPZ Vaccine in 18 to 54 malaria-naïve, healthy adult volunteers receiving 9x10^5, 1.35x10^6, or 2.7x10^6 PfSPZ per dose and a total…
- Trial name
- NCT02704533
- Testing
- PfSPZ Vaccine, PfSPZ Challenge (NF54), PfSPZ Challenge (7G8)
- Where
- Germany
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.